ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report) shares shot up 0.3% on Monday . The stock traded as high as $62.96 and last traded at $62.38. 35,751 shares traded hands during trading, a decline of 5% from the average session volume of 37,731 shares. The stock had previously closed at $62.20.
ALPS Medical Breakthroughs ETF Stock Performance
The business has a fifty day simple moving average of $65.94 and a 200 day simple moving average of $58.75.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Harbor Investment Advisory LLC purchased a new stake in ALPS Medical Breakthroughs ETF during the second quarter valued at about $29,000. Virtu Financial LLC raised its holdings in ALPS Medical Breakthroughs ETF by 7.3% during the 4th quarter. Virtu Financial LLC now owns 17,967 shares of the company’s stock valued at $920,000 after buying an additional 1,229 shares during the last quarter. Kestra Advisory Services LLC grew its stake in shares of ALPS Medical Breakthroughs ETF by 27.6% in the first quarter. Kestra Advisory Services LLC now owns 8,186 shares of the company’s stock worth $428,000 after purchasing an additional 1,772 shares during the last quarter. Sterling Investment Advisors Ltd. grew its position in shares of ALPS Medical Breakthroughs ETF by 8.1% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 23,800 shares of the company’s stock worth $1,539,000 after buying an additional 1,775 shares during the last quarter. Finally, Silver Oak Securities Incorporated increased its position in ALPS Medical Breakthroughs ETF by 24.4% during the 1st quarter. Silver Oak Securities Incorporated now owns 16,589 shares of the company’s stock valued at $868,000 after purchasing an additional 3,254 shares during the period.
ALPS Medical Breakthroughs ETF Company Profile
The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.
Further Reading
- Five stocks we like better than ALPS Medical Breakthroughs ETF
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
Receive News & Ratings for ALPS Medical Breakthroughs ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALPS Medical Breakthroughs ETF and related companies with MarketBeat.com's FREE daily email newsletter.
